Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

BloomWell Rx vs Claya

BloomWell Rx
Graded #298

Lower grade

vs+1.5
Claya
Graded #268

Higher grade

The verdict

Claya takes it — 62.8/100 to 61.3/100, but only just.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors. BloomWell Rx is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBloomWell Rx +12
54
42
Dose & formulationClaya +11
64
75
Clinical oversightClaya +11
71
82
Labs & monitoringEven
53
53
FulfillmentBloomWell Rx +3
70
67
Contract termsClaya +6
55
61
BloomWell Rx · left barClaya · right bar

The numbers

MetricBloomWell RxClaya
WeighScore61.3/10062.8/100
GradeCC
Scorecard rank#298#268
Semaglutide$199/mo (starting dose, compounded)$299/mo (compounded)
Tirzepatide$249/mo (starting dose, compounded)$299/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
BloomWell Rx

Graded #298 · C

Strengths

  • Transparent pricing — compounded semaglutide from $199/mo, tirzepatide (GLP-1/GIP) from $249/mo
  • Free initial visit; fully online process with flexible dosing options
  • Discloses meds are compounded by a licensed third-party pharmacy; also offers NAD+, sermorelin, glutathione
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)

Where it loses points

  • 'Starts at' pricing — final cost depends on dose and plan
  • Compounding pharmacy partner not named ('licensed third-party pharmacy')
  • Not LegitScript-certified (no certification displayed)
  • Operating medical entity not clearly named (site operated by a marketing agency)
Claya

Graded #268 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard